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Abstract 
We report a case of nephrotic syndrome and acute renal failure apparently induced by 
sunitinib. A 67-year-old man with a history of metastatic renal cell carcinoma presented 
with progressive kidney dysfunction with proteinuria, general edema, and body weight 
gain of 21 kg after undergoing 3 weeks of sunitinib therapy. The patient had taken no 
other over-the-counter medications, and all other possible causes of nephrotic syndrome 
were excluded. The Naranjo Adverse Drug Reaction Probability Scale score for this event 
was 6, indicating a high probability that the observed presentations were associated 
with use of the drug. However, despite the discontinuation of sunitinib, his condition 
deteriorated, and hemodialysis was initiated for respiratory distress. A renal biopsy was 
performed, which revealed ischemic acute tubular necrosis with minimal change 
nephropathy. In conclusion, nephrologists and oncologists should be aware that 
nephrotic syndrome with ischemic acute tubular necrosis is a possible adverse effect of 
sunitinib. For early diagnosis of this condition and to avoid renal damage, we 
recommend differential diagnosis of serum creatinine and proteinuria in patients 
undergoing sunitinib therapy. 
 
Introduction 
Sunitinib is a small molecule that inhibits multiple tyrosine kinase receptors. In 2006, 
the United States Food and Drug Administration approved this drug for treating clear cell 
metastatic renal cell carcinoma [1]. In patients given sunitinib, median progression-free 
survival is significantly longer than in patients given the standard treatment with 
interferon-α, and some patients exhibit tumor regression [2]. Its known adverse effects  
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include fatigue, malaise, diarrhea, skin abnormalities, and cytopenia. This report is the 
first to describe a case of nephrotic syndrome and ischemic acute tubular necrosis 
apparently related to sunitinib therapy. 
Case Report 
We report the case of a 67-year-old man who was treated with sunitinib for metastatic clear cell renal 
cell carcinoma. In August 2008, he was diagnosed with right huge renal tumor with inferior vena cava 
compression in the Chang Gung Memorial Hospital, Kaohsiung Branch, and then he visited our 
urology outpatient department for a tumor biopsy and management. After admission in October 2008, 
he refused the tumor biopsy, but agreed to tyrosine kinase inhibitor sunitinib for suspected metastatic 
renal cell carcinoma. Before beginning the sunitinib therapy, blood pressure was 116/61 mm Hg with 
medical control for hypertension, serum creatinine was 1.1 mg/dl, albumin level was 4.0 g/dl, and 
cholesterol was 57 mg/dl, triglyceride was 114 mg/dl and the patient had no proteinuria. After starting 
the sunitinib therapy with 37.5 mg daily at the end of November, he began to exhibit foamy urine and 
gradually decreasing urine excretion as well as a 21-kg weight gain. His response to furosemide and 
water with salt restriction was poor, and general edema, dyspnea on exertion, and oliguria developed. 
After 3 weeks of therapy, sunitinib was discontinued on December 18, 2008. However, urine excretion 
and edema showed no improvement 2 weeks after discontinuing sunitinib (fig. 1). The patient was re-
admitted in January 2009 with serum creatinine 5.1 mg/dl, albumin level 1.5 g/dl, and sugar level 107 
mg/dl. Urinalysis revealed proteinuria with bland sediment. No non-steroid anti-inflammatory drugs, 
antibiotics, or herbal supplements were used throughout the course of the sunitinib therapy. Physical 
examination revealed high blood pressure 161/83 mm Hg, jugular venous pressure 10 cm, bilateral basal 
fine crackle breathing sounds, severe lower leg and scrotal edema without skin rash and arthralgia. Spot 
urine protein/creatinine was 20.0 (g/g). Serum complement, anti-neutrophil antibody, cryoglobulin, 
protein electrophoresis, and rheumatoid factor were negative, and no hematological features of 
thrombotic microangiopathy were observed. Renal sonography revealed a large (14.8 × 13.3 cm) tumor 
and normal left renal size without hydronephrosis. Response to high-dose furosemide and albumin 
supplement was poor, and temporal hemodialysis was done for 2 weeks due to respiratory distress. After 
a discussion with the patient and his family, a right tumor and left renal biopsy was performed on 
January 23, 2009. Clear cell renal cell carcinoma was confirmed. Immunofluorescence revealed negative 
IgG, IgA, IgM, C1q, C3, kappa and lambda light deposition, and glomeruli with no remarkable change 
other than mild mesangial expansion. Electron microscopy showed normal thickness of the glomerular 
basement membrane and segmental subendothelial widening, mild small dense deposits in the 
mesangial area, marked and extensive epithelial cell foot process effacement, moderate epithelial cell 
microvillous transformation (fig. 2a), attenuation of the brush border, and sloughing tubule cell (fig. 
2b). After temporal hemodialysis, urine quantity improved. Serum creatinine also improved (creatinine 
2.8 mg/dl [213.53 μmol/l]). However, daily protein loss increased to 48.1 g despite having discontinued 
sunitinib for 10 weeks. The urine protein loss decreased to 9.85 g/day and serum creatinine to 1.8 mg/dl 
after the patient was given prednisolone 30 mg daily for 4 weeks. 
Discussion 
The patient had taken no other over-the-counter medications, and all other possible 
causes of minimal change nephropathy were excluded. Before beginning the sunitinib 
therapy, he was proteinuria-free and had normal renal function. The Naranjo Adverse 
Drug Reaction Probability Scale score for this event was 6, indicating a probable 
association of the event with the drug. Sunitinib is an oral, small-molecule, multi-targeted 
receptor tyrosine kinase inhibitor of targets such as vascular endothelial growth factor 
(VEGF) and platelet-derived growth factor receptor. The drug is administered orally once 
daily in a 4-weeks-on/2-weeks-off cycle. The VEGF is important for maintaining normal 
glomerular endothelial function. In normal mice and rats, circulating VEGF-A can 
reportedly be neutralized by injection of anti-VEGF-A antibodies, or soluble VEGF-R1 
induced proteinuria, glomerular endothelial cell detachment, and suppression of nephrin, 
an important protein for maintaining the glomerular slit diaphragm. Such findings 
implicate the role of VEGF in the maintenance of the glomerular filtration barrier that  
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prevents leakage of plasma proteins into urine. Proteinuria is common in mice treated 
with soluble VEGF-R1 and in humans treated with anti-VEGF antibody [3, 4]. However, 
the patient described in this report developed persistent proteinuria and required dialysis 
even after discontinuing sunitinib. Although a few reports have described renal 
dysfunction induced
 by sunitinib, including acute interstitial nephritis [5] and thrombotic 
microangiopathy [6], this study is the first to report nephrotic syndrome with acute renal 
failure and ischemic acute tubular necrosis associated
 with this agent, and this is the first 
report of diagnosis by histological study. We suspect that sunitinib may induce nephrotic
 
syndrome by an immune reaction combined with amplification of the underlying 
pathogenesis of minimal change nephropathy, which may present with a transient 
episode of circulatory insufficiency during diuretic treatment and induce ischemic acute 
tubular necrosis [7]. Oral anticancer
 agents such as sunitinib are generally considered 
safer than
 other anticancer agents and more tolerable by patients with
 poor condition or 
by patients with organ failure that is untreatable by standard cytotoxic chemotherapy. 
This case report suggests that oncologists and nephrologists should be vigilant for 
possible minimal change nephropathy and ischemic acute tubular necrosis related to 
sunitinib treatment, especially in patients with renal cell carcinoma. 
Until now, no guidelines for monitoring serum creatinine in patients undergoing 
sunitinib therapy have been proposed. We recommend monitoring of serum creatinine 
and proteinuria immediately after initiating sunitinib therapy for early diagnosis of 
minimal change nephropathy and ischemic acute tubular necrosis and to avoid renal 
damage. 
 
 
 
 
 
Fig. 1. Kidney function assessed by serum creatinine concentration and body weight after sunitinib 
treatment in a 67-year-old male with a history of metastatic renal cell carcinoma. 
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Fig. 2. a Marked epithelial cell foot process effacement and extensive and moderate epithelial cell 
microvillous transformation without subendothelial electronlucent fluffy material depositions (signs of 
coagulation). b Attenuation of the brush border and sloughing tubule cell consistent with ischemic 
acute tubular necrosis. 
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